COMMUNIQUÉS West-GlobeNewswire

RadNet Enters Indiana with Acquisition of Northwest Radiology
03/02/2026
Purchase of six imaging centers establishes RadNet’s entry into the Midwestern United States LOS ANGELES, Feb. 03, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost- [...]
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
03/02/2026
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a [...]
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
03/02/2026
Brings more than 25 years of biopharma business development and corporate strategy expertise BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company [...]
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
03/02/2026
LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable Americans [...]
OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity
03/02/2026
OrthoPediatrics partner iotaMotion receives FDA clearance for use of its iotaSOFT® cochlear implant insertion system in patients four years and older WARSAW, Ind., Feb. 03, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp [...]
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
03/02/2026
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the [...]
TSC Life Receives FDA Clearance for Pediatric Use with Fluido® Compact System, a Blood & Fluid Warmer, in the U.S. and Canada
03/02/2026
DENVER, Feb. 03, 2026 (GLOBE NEWSWIRE) -- TSC Life , a global medtech company redefining healthcare with high-performance devices for temperature management and endoscopy, announced today that the U.S. Food and Drug [...]
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
03/02/2026
This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. [...]
Peer-reviewed publication validates Cylinder Health savings
03/02/2026
Peer-reviewed study shows 5:1 ROI for employer GI benefit program and savings of 18% compared to controls Study in The American Journal of Managed Care finds reduced overall medical spend and acute care utilization [...]
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2
03/02/2026
Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with Charcot-Marie-Tooth disease (CMT) [...]
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
03/02/2026
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to [...]
The Ensign Group Acquires Real Estate and Operations in Texas
03/02/2026
SAN JUAN CAPISTRANO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event
03/02/2026
“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences" Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact drug development [...]
The Ensign Group Buys Real Estate and Operations in Wisconsin
03/02/2026
SAN JUAN CAPISTRANO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
03/02/2026
Cardiac dosing limit removed and path forward to dose selection identified LONDON and PHILADELPHIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage [...]
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
03/02/2026
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
Tilray Brands Ignites Championship Sunday: Nationwide Tap Room Events, Big Game Day Deals, and Fan Experiences Announced
03/02/2026
Gear up for game day, Sunday, February 8, 2026, with ultimate fan experiences, beer, wings, whiskey, and more at SweetWater Brewing Co., Montauk Brewing Co., Breckenridge Brewery, Blue Point Brewing Co., 10 Barrel [...]
PreciseOnco research consortium awarded EUR 14.9 million IHI grant to drive breakthroughs in precision cancer treatment
03/02/2026
February 3, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the Philips-coordinated research consortium will combine advanced medical imaging, robotic guidance technologies, and AI to standardize and [...]
HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones
03/02/2026
HemostOD awarded CHF 2 million Innosuisse grant to support key development milestones Lausanne, Switzerland — 03 February 2026 – HemostOD, a private Swiss company pioneering the ex vivo manufacturing of donor-free, off- [...]

Pages